Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of.
Transferred anti-IL 18 monoclonal antibody product to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK. | August 4, 2022
Form 8-K Avalo Therapeutics, Inc For: Aug 04 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics - read this article along with other careers information, tips and advice on BioSpace
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.